By Denny Jacob

ModeX Therapeutics, a OPKO Health company, was awarded a contract hailing from the Biomedical Advanced Research and Development Authority to advance candidates designed to address a range of public health threats in viral infectious diseases.

The clinical-stage biopharmaceutical company said the awarded funding would enable research, development and clinical evaluation of multispecific antibodies based on its proprietary technology.

The contract includes an initial $59 million for the development and execution of a clinical trial for a multispecific antibody with broad neutralizing abilities against known variants of the coronavirus known as SARS-CoV-2. Additional funding of up to $109 million may be available upon hitting certain milestones.

The Biomedical Advanced Research and Development Authority is part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

September 28, 2023 16:55 ET (20:55 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Opko Health (NASDAQ:OPK)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024 Click aqui para mais gráficos Opko Health.
Opko Health (NASDAQ:OPK)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024 Click aqui para mais gráficos Opko Health.